NVGN - 19787

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
    PR Newswire

    St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's investigational new drug, GDC-0084 in diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas, which represent a group of childhood brain cancers with high unmet need. Dr. Christopher Tinkle, co-Lead Investigator on the study, commented, "to date, thirteen patients have received GDC-0084 in our study.

  • We're sorry this is all we were able to find about this topic.